Newsroom

TAMPA, Fla.--(BUSINESS WIRE)--AI Med Consult, a HIPAA-compliant patient engagement platform for aesthetic surgery practices, today announced that it went live on the ModMed SynapSYS Marketplace as an integration partner. Practices running ModMed can now find and connect AI Med Consult directly through the marketplace and keep working in the EMR they already use. Practices lose consultations in the gap between an inquiry and a booking. A prospective patient calls after hours, submits a web form...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest US Equity Max Buffer UCITS ETF - March 21.10.2026 MMAR.LN IE0002PPCMH6 50,002.00 USD 1,352,735.76 27.054  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Moderate Buffer UCITS ETF - February 21.10.2026 GFEB.LN IE000X8M8M80  650,002.00 USD  26,271,276.06   40.417  ...

MIAMI--(BUSINESS WIRE)--Picsart, la plataforma de producción y distribución de contenido multimedia con inteligencia artificial (IA) que utilizan más de 100 millones de creadores y empresas de todo el mundo para crear, promocionar y monetizar contenido, anunció hoy el lanzamiento de Marketing Studio. La nueva herramienta reúne la creación de contenido, la estrategia publicitaria, las pruebas creativas y la distribución paga en una experiencia integrada. Ya disponible, Marketing Studio combina i...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Bloomberg Space Economy UCITS ETF 21.10.2026 FSPC.LN IE000ANMCD25 175,002.00 USD 3,332,949.10 19.045  ...

DIJON, France--(BUSINESS WIRE)--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN : FR001400CM63 ; Mnémonique : ALOPM), entreprise biopharmaceutique spécialisée en médecine de précision pour le traitement des cancers résistants et métastatiques, annonce ses résultats financiers du premier semestre 2026, clos le 30 juin 2026. Philippe GENNE, Président-Directeur Général d’Oncodesign Precision Medicine, déclare : « Le parcours d’OPM se poursuit avec en ligne de mire son objectif thérapeut...

DIJON, France--(BUSINESS WIRE)--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, announces its financial results for the first half of 2026, ended June 30, 2026. Philippe GENNE, Chairman and CEO of Oncodesign Precision Medicine, comments: “OPM continues to move towards its therapeutic objective, with two active compounds reaching the clin...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest S&P 500 Dividend Aristocrats Target Income UCITS ETF 21.10.2026 KNG.LN IE000SNMGYT5 1,250,002.00 USD  25,955,867.48   20.765  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust FactorFX UCITS ETF 21.10.2026 FXGB LN IE00BD5HBR05   54,467.00 GBP   1,181,861.70   29.042  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Moderate Buffer UCITS ETF - November 21.10.2026 GNOV LN IE000OJ31JQ4  800,002.00 USD  30,473,487.84   38.092  ...